

**REMARKS**

Claims 19, 21 – 30 and 33 - 35 are currently pending.

Primary Ex. Pryor and SPE Marschel are thanked for their kindness and helpful guidance to the undersigned during the personal interview conducted August 19, 2008. Applicants' separate record of the substance of the interview is incorporated into this response.

The only rejections of record are: the rejection of all pending claims under §112, first paragraph; and the rejection of claims 19 and 21-30 under §102(b).

Concerning the §112, first paragraph, rejection, during the interview, Applicants' attorney offered to amend claim 19 to remove the recitation of "susceptible to", and Ex. Pryor tentatively agreed that such an amendment would obviate the rejection. It was further suggested by the examiners to delete this 'preventive' or 'prophylactic' aspect from the specification (in regard to the definition of 'treatment' or 'treating').

By this paper, both the amendment to the specification and to claim 19 are made. Accordingly, withdraw of this rejection is respectfully requested.

Concerning the §102(b) rejection, the Examiner construed "*a* guanidine salt" to broadly mean a salt of any guanidine, including modifications to the guanidine molecule (such as the N, N – disubstituted guanidines described in the '946 patent). After discussion with the examiners, it was understood that by the terminology Applicants had intended that the salts be those of only the parent moiety "guanidine", and not modifications to or derivatives of guanidine. It was agreed at the interview that Applicants' interpretation would be made of record in this case (by this paper and by Primary Examiner Pryor noting this interpretation as distinguishing the present from the prior art – the '946 patent – in the "Reasons for Allowance" in the expected notice of

August 19, 2008  
US Serial No. 09/835,537

allowance. Applicants kindly request that the rejection be withdrawn in view of such remarks on the record.

It is believed that this supplemental response puts this application in condition for allowance.

Respectfully submitted,

/M. Elisa Lane/  
M. Elisa Lane  
Attorney for Applicants  
Registration No. 34,409

Panacea Pharmaceuticals, Inc.  
207 Perry Parkway, Suite 2  
Gaithersburg, Maryland 20877  
Tel: (240) 454-8016 (direct)  
[elisalane@panaceapharma.com](mailto:elisalane@panaceapharma.com)